Pembrolizumab doubles time to disease progression in patients with advanced colorectal cancer with specific DNA mutations

'Immunotherapies like pembrolizumab have proved to be effective as second-line treatments for advanced disease. Now,... we are starting to see significant efficacy for immunotherapies as first-line treatment for advanced cancers with specific genetic signatures...,' said ASCO President Howard Burris

Join OnMedica and benefit from:

  • Bitesize CPD and easy to digest content, free for UK-based GPs and specialist doctors
  • High-quality, evidence-based content developed by expert editors and clinicians
  • Articles, quizzes, videos, visual summaries and more
  • Regulatory alerts and round-up of medical journals
  • New content added daily, so you know you’re always up to date
Register

Existing members Sign in

No comments yet.